The combination of a lung cancer vaccine plus chemotherapy has been proven to help more patients live without their cancer progressing than chemotherapy alone, a study has revealed.

The research, led by the University of Strasbourg, involved 148 patients with non-small-cell lung cancer, the most common form of the disease.

Results published in The Lancet Oncology showed that 43% of the 74 patients treated with Trasgene’s TG4010 vaccine in combination with chemotherapy survived for six months without the disease progressing, while the progression-free survival rate in the 74 patients treated with chemotherapy alone was 35%.

TG4010 is designed to trigger the immune system and target the MUC1 protein, which is overproduced by tumour cells in advanced lung cancer.

France-based gene therapy group Transgene funded the phase IIb trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.